Most active pharmaceutical ingredients (APIs) are not suitable for “passive” loading into nano-liposomes. The desired concentration in the nano-liposomes is hard to achieve. Consequently, the therapeutic efficacy in humans is not sufficient. Remote drug loading into nano-liposomes is in most cases the best method for achieving high concentrations of API per nano-liposome that enables therapeutically viable API-loaded nano-liposomes, referred to as nano-drugs.
The inventors constructed computational methods to identify APIs that can achieve the desired high concentrations in nano-liposomes by remote loading.
- Controlled drug release
- Stable upon storage
Applications for use:
The technology entails modeling structural drug descriptors for loading and leakage properties of liposomal drugs for the rational identification of new liposomal drug candidates
This group of molecules, having diverse pharmacological activities, may be the basis for future liposomal drug development.